Patient Subsetting

MetPM™ Enabled Precision Medicine

Cellular metabolism is the fundamental network of mechanisms that drives immune cell function in health and disease. At Rheos, we combine foundational insights into cellular metabolism of immune cells with deep expertise in bioinformatic analysis to bring precision medicine to highly heterogenous autoimmune and inflammatory diseases.

We have developed proprietary computational methods for transcriptional analysis of metabolic function within the MetPM platform to discover clinically relevant and actionable patient subsets. We have identified clinically actionable patient subsets through our analyses of systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) and chronic graft versus host disease (cGVHD). Applying the same transcriptional analysis, MetPM successfully resolved a heterogeneous population of rheumatoid arthritis patients into distinct subsets that match treatment response.

MetPM Platform - Patient Subsetting

MetPM Uncovers Actionable Patient Subsets in Autoimmune and Inflammatory Diseases
By examining the differences between patients both across and within disease states, Rheos is uniquely able to discover and apply molecular signatures to stratify and select patients within highly heterogenous autoimmune and inflammatory diseases. Typical gene-based clustering approach reveals no patterns, but Rheos’s MetPM clustering approach reveals distinct and novel patient subsets.